Meeting
2024 ASCO Annual Meeting
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).
Authors
Celine Yeh
Memorial Sloan Kettering Cancer Center, New York, NY
Celine Yeh , Emily Harrold , Fergus Keane , Jenna Cohen Sinopoli , Michael Bonner Foote , Andrea Cercek , Rona Yaeger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3542)
DOI
10.1200/JCO.2024.42.16_suppl.3542
Abstract #
3542
Poster Bd #
205
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
First Author: Sandra Algaze
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
First Author: Anwaar Saeed
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler